Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 Risk of Recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy alone-Reference-Cited by-同舟云学术

Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 Risk of Recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy alone

Published:2014-02 Issue:2 Volume:25 Page:339-345
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Gnant M.,Filipits M.,Greil R.,Stoeger H.,Rudas M.,Bago-Horvath Z.,Mlineritsch B.,Kwasny W.,Knauer M.,Singer C.,Jakesz R.,Dubsky P.,Fitzal F.,Bartsch R.,Steger G.,Balic M.,Ressler S.,Cowens J.W.,Storhoff J.,Ferree S.,Schaper C.,Liu S.,Fesl C.,Nielsen T.O.

Funder

AstraZeneca

NanoString Technologies

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/25/2/339/16698957/mdt494.pdf

Reference17 articles.

1. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer;Paik;N Engl J Med,2004

2. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials;Early Breast Cancer Trialists’ Collaborative Group (EBCTCG);Lancet,2005